You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 6,849,401


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,849,401
Title: Methods for determining coat color genotypes in pigs
Abstract:Methods for determining coat color genotypes in pigs are provided. In particular, these methods are based on determining whether a mutation is/is not present at one or more exon/intron splice sites of the KIT gene. Kits for carrying out such methods are also described.
Inventor(s): Andersson; Leif (Uppsala, SE), Marklund; Stefan (Uppsala, SE), Kijas; James (Ithaca, NY), Moller; Maria (Uppsala, SE), Wales; Richard (Cambridge, GB)
Assignee: Melica HB (SE)
Application Number:09/550,605
Patent Claims:1. A method for determining coat colour genotype in a pig which comprises: (a) obtaining a sample of pig nucleic acid; and (b) analysing the nucleic acid obtained in (a) to determine whether a mutation is/is not present at an exon 17/intron 17 splice site of a KIT gene, wherein the mutation consists of the substitution of the G in the conserved GT pair by A.

2. The method according to claim 1, wherein the sample of nucleic acid is amplified prior to analysis.

3. The method according to claim 2, wherein the nucleic acid is genomic DNA.

4. The method according to claim 3, wherein amplification is carried out using PCR and at least one pair of suitable primers.

5. The method according to claim 4, wherein the pair of suitable primers is: 5'-GTA TTC ACA GAG ACT TGG CGG C-3' (SEQ. ID No. 1); and 5'-AAA CCT GCA AGG AAA ATC CTT CAC GG-3' (SEQ. ID No. 2).

6. The method according to claim 3, wherein after amplification the nucleic acid is treated with a restriction enzyme, followed by analysis of fragment lengths.

7. The method according to claim 6, wherein the nucleic acid is treated with the restriction enzyme NlaIII.

8. The method according to claim 6, wherein the ratio of restriction fragment lengths is determined.

9. The method according to claim 2, wherein the nucleic acid is mRNA.

10. The method according to claim 9, wherein the nucleic acid is amplified using RT-PCR.

11. The method according to claim 10, wherein the length of RT-PCR product is determined.

12. A method for determining coat colour genotype in a pig which comprises the step of analysing a sample of pig KIT protein to determine whether the protein is a splice variant protein produced by the substitution of G in the conserved GT pair by A, at an exon 17/intron 17 splice site of a KIT gene, said splice variant protein being correlated with coat colour genotype.

13. A kit for use in determining the coat colour genotype of a pig which comprises one or more reagents for carrying out PCR and the following pair of primers: 5'-GTA TTC ACA GAG ACT TGG CGG C-3' (SEQ ID No. 1); 5'-AAA CCT GCA AGG AAA ATC CTT CAC GG-3' (SEQ ID No. 2).

14. The method of claim 1, wherein the presence or absence of said mutation is determined in each copy of the KIT gene in the pig's genome, and the ratio of the number of KIT genes lacking the mutation to the number of KIT genes containing the mutation is determined.

15. The method according to claim 7, wherein the ratio of restriction fragment lengths is determined.

Details for Patent 6,849,401

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2017-10-17
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2017-10-17
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2017-10-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.